AbbVie Inc. the Spinoff for 2013
AbbVie Inc (ABBV) just started trading in 2013. AbbVie is the first 'Spinoff' for Wall Street in the New Year and has separated from Abbott Labs (ABT).
AbbVie was the pharmaceutical division of Abbott Labs, so far its bounced from $34 to $35 per share. This spinoff has been in motion since 2011. Before the deal, Abbott was one of the largest healthcare companies in the world. The aging world population is going to keep popping pills made by AbbVie including the anti-inflammation drug Humira, the popular painkiller Vicodin, and cholesterol drug Niaspan.
Abbott's chairman and CEO Miles White called the event "the most transformative action" in the company's 125-history. AbbVie CEO Richard Gonzalez said that with his company's existing assets and focus on innovation "we intend to create significant value for our shareholders."
Bottom line: Time will tell if this spinoff will be successful and Wells Fargo is the first to set a price target of $33 to $34. For now add this stock to your watch list and as more information becomes available place your trading accordingly. To review the company check out their website at www.abbvie.com/
Best of the Blogs
Scanning and identifying the best blog entries every hour
- Sorry Folks, The North Koreans Hacked The "Global Recovery" | ZeroHedge
- The Stuff Is Already Hitting the Fan in the Currency Markets | ZeroHedge
- Preliminary Michigan Consumer Sentiment for December Surges | Financial Sense
- Fed Cat Bounce: Stocks Soar Most In 3 Years As Crude Crash Continues | ZeroHedge
- More To Ruble's Collapse Than Meets The Eye? | ZeroHedge
- Draghi Now Has All the Ammunition He Needs for QE - Implementation Still a Problem | Financial Sense
- Closing a Chapter, Opening an Old One Again | iBankCoin.com
The most relevant financial news and articles from the Internets
- After A Horrible Year, 72-Year-Old Publicis Boss Maurice Lévy Said... | Business Insider
- Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve) | TheStreet.com
- Aussies Smith, Johnson blast India bowlers to... | Business Insider
- Notable 52-Week... | StreetInsider.com
- Why Netflix Is Doing a Deal With DISH Network's Charlie Ergen | TheStreet.com
- Hallucinogens Legally Sold as 'Bath Salts' a New Threat | BusinessWeek
- The US Is Ready To Blame North Korea For The Sony... | Business Insider